trending Market Intelligence /marketintelligence/en/news-insights/trending/W0_fmb7WTyxqaPk1_J5yDQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Taiwan Leader Biotech H2 loss widens YOY

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID 19 Impact Recovery Media Telecom and Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Taiwan Leader Biotech H2 loss widens YOY

Taiwan Leader Biotech Corp. said its second-half normalized net income amounted to a loss of NT$1.10 per share, compared with a loss of 56 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$36.5 million, compared with a loss of NT$15.8 million in the year-earlier period.

Total revenue grew 32.5% on an annual basis to NT$9.6 million from NT$7.2 million, and total operating expenses grew on an annual basis to NT$67.7 million from NT$32.2 million.

Reported net income came to a loss of NT$58.6 million, or a loss of NT$1.76 per share, compared to a loss of NT$24.6 million, or a loss of 87 cents per share, in the year-earlier period.

For the year, the company's normalized net income totaled a loss of NT$1.68 per share, compared with a loss of NT$1.20 per share in the prior year.

Normalized net income was a loss of NT$54.0 million, compared with a loss of NT$33.6 million in the prior year.

Full-year total revenue grew 44.7% on an annual basis to NT$19.3 million from NT$13.3 million, and total operating expenses increased 59.7% year over year to NT$105.3 million from NT$66.0 million.

The company said reported net income totaled a loss of NT$86.6 million, or a loss of NT$2.69 per share, in the full year, compared with a loss of NT$53.1 million, or a loss of NT$1.90 per share, the prior year.

As of Feb. 15, US$1 was equivalent to NT$33.16.